Stryker Corporation’s return to revenue growth in the third quarter was led by demand for capital products, especially Stryker’s Mako robotic surgery system.
For the third quarter, the company reported sales of $3.7bn, representing 3.3% year-over-year growth on an organic basis. Unit volume was up 4.7%, but partially offset 1.4% from lower prices,...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?